XLO fundamentals
Xilio Therapeutics, Inc. financial statements, including revenue, expenses, profit, and loss
The total revenue of XLO for the last quarter is 2.26 M USD, and it's 3.99% lower compared to the previous quarter. The net income of Q3 24 is -14.02 M USD.
Q1 '20
Q2 '20
Q3 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Total revenue
Gross profit
Operating income
Pretax income
Net income
Currency: USD
Q1 '20
Q2 '20
Q3 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
TTM